Table 1 Clinical characteristics of 41 patients
From: MicroRNA-136-3p inhibits glioma tumorigenesis in vitro and in vivo by targeting KLF7
Clinicopathologic feature | n (%) | miR-136-3p | p value | ||
|---|---|---|---|---|---|
High | Low | mean ± SEM | |||
Age | p = 0.3603 | ||||
≤ 40 | 19 (46.34%) | 10 | 9 | 1.89 ± 0.18 | |
≥ 40 | 22 (53.66%) | 10 | 12 | 1.92 ± 0.17 | |
Gender | p = 0.2104 | ||||
Female | 18 (43.90%) | 8 | 10 | 1.91 ± 0.19 | |
Male | 24 (56.10%) | 13 | 11 | 1.79 ± 0.18 | |
Surgery | p = 0.4472 | ||||
Biopsy | 7 (17.07%) | 4 | 3 | 2.03 ± 0.20 | |
Partial resection | 14 (34.15%) | 5 | 9 | 2.15 ± 0.18 | |
Gross total resection | 20 (48.78%) | 9 | 11 | 2.07 ± 0.21 | |
WHO grade (%) | p < 0.0001 | ||||
ІІ | 8 (30.00%) | 2 | 6 | 2.91 ± 0.26 | |
ІІІ | 12 (33.33%) | 4 | 8 | 2.05 ± 0.21 | |
IV | 21 (36.67%) | 5 | 17 | 1.68 ± 0.17 | |
Low expression | 18 (43.90%) | 13 | 5 | 4.19 ± 0.41 | p < 0.0001 |
High expression | 23 (56.10%) | 4 | 19 | 1.98 ± 0.22 | |
Tumor size | p = 0.3514 | ||||
< 4 cm | 16 (39.02%) | 7 | 8 | 2.18 ± 0.21 | |
≥ 4 cm | 25 (60.98%) | 11 | 14 | 2.24 ± 0.23 | |